Pulmatrix (NASDAQ:PULM – Get Free Report) and Exactus (OTCMKTS:EXDI – Get Free Report) are both small-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their valuation, earnings, analyst recommendations, institutional ownership, dividends, profitability and risk.
Profitability
This table compares Pulmatrix and Exactus’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Pulmatrix | N/A | -125.65% | -95.19% |
| Exactus | N/A | -3,272.69% | -185.29% |
Earnings and Valuation
This table compares Pulmatrix and Exactus”s top-line revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Pulmatrix | $7.81 million | 0.71 | -$5.16 million | ($1.10) | -1.37 |
| Exactus | $2.07 million | 0.00 | -$9.46 million | N/A | N/A |
Pulmatrix has higher revenue and earnings than Exactus.
Volatility and Risk
Pulmatrix has a beta of 1.91, suggesting that its share price is 91% more volatile than the S&P 500. Comparatively, Exactus has a beta of 4.21, suggesting that its share price is 321% more volatile than the S&P 500.
Analyst Recommendations
This is a breakdown of recent ratings and target prices for Pulmatrix and Exactus, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Pulmatrix | 1 | 0 | 0 | 0 | 1.00 |
| Exactus | 0 | 0 | 0 | 0 | 0.00 |
Given Exactus’ higher possible upside, analysts plainly believe Exactus is more favorable than Pulmatrix.
Insider and Institutional Ownership
11.8% of Pulmatrix shares are owned by institutional investors. Comparatively, 0.1% of Exactus shares are owned by institutional investors. 0.6% of Pulmatrix shares are owned by insiders. Comparatively, 65.0% of Exactus shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
Summary
Pulmatrix beats Exactus on 7 of the 10 factors compared between the two stocks.
About Pulmatrix
Pulmatrix, Inc., a clinical stage biotechnology company, focused on development of novel inhaled therapeutic products to prevent and treat respiratory and other diseases with unmet medical needs in the United States. The company offers iSPERSE, an engineered dry powder delivery platform, which enables delivery of small or large molecule drugs to the lungs by inhalation for local or systemic applications. It engages in developing PUR1800, a narrow spectrum kinase inhibitor completed Phase 1b clinical trials for the treatment of acute exacerbations in chronic obstructive pulmonary disease; PUR1900 for the treatment of allergic bronchopulmonary aspergillosis in patients with asthma and cystic fibrosis; and PUR3100, an iSPERSE formulation of dihydroergotamine which is in Phase 1 for the treatment of acute migraine. It has a license agreement with RespiVert Ltd. for access to a portfolio of kinase inhibitor drug candidates. The company was founded in 2003 and is headquartered in Bedford, Massachusetts.
About Exactus
Exactus, Inc., is a farmer and manufacturer of hemp-derived phytocannabinoid products. The company sells its CBD products through its Green Goddess brand and third-party resellers. Exactus is engaged in producing industrial hemp from farms in Oregon and plans to extract and manufacture directly through cGMP facilities. Industrial hemp is a type of cannabis, defined by the federal government as having THC (tetrahydrocannabinol) content of 0.3 percent or less. THC is the psychoactive compound found in cannabis.
Receive News & Ratings for Pulmatrix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pulmatrix and related companies with MarketBeat.com's FREE daily email newsletter.
